[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"biomarker:interleukin-13-receptor-alpha2-subunit":3},{"name":4,"total":5,"recruiting":5,"trials":6},"Interleukin-13 Receptor alpha2 Subunit",1,[7],{"nct_id":8,"title":9,"phases":10,"status":12,"updated_at":13,"content_modified":14},"NCT04119024","Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors",[11],"Phase 1","RECRUITING","2026-08-26T02:17:50.500039Z","2026-05-05T02:43:27.844111Z"]